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Pharmacokinetics of Quinapril and its
Active Metabolite Quinaprilat During
Continuous Ambulatory Peritoneal Dialysis
R. D. Swartz, MD, B. Starmann, RN, A. M. Horvath, S. C. Olson, PhD, and E. L. Posvar, MD
The pharmacokinetics of quinapril, a novel angiotensin converting enzyme (ACE) inhib-
itor, and its active metabolite, quinaprilat, were determined following a single 20-mg oral
dose of quinapril in six patients with chronic renal failure maintained on continuous
ambulatory peritoneal dialysis (CAPD). Overall, quinapril was well tolerated by these
CAPD patients, with mild and transient side effects, not unexpected in this clinical
setting, which included pruritus, headache, nausea, and cough. Blood pressure reduction
was observed in four of six patients, with onset reliably two to four hours after dosing and
duration up to 48 hours, associated with quinaprilat concentrations in plasma above 90
ng/mL for at least 33 hours postdose. Two patients experienced significant hypotension,
systolic blood pressure below 90 mm Hg, which responded promptly to oral fluid admin-
istration and/or reduction in dial ysate tonicity. The pharmacokinetic profile of quinapril
in these CAPD patients was not significantly different from that previously observed in
healthy subjects with normal renal function and in patients with moderate to severe
renal dysfunction not yet requiring dialysis (RDND). The apparent elimination half-life
of quinapril was approximately one hour, with negligible dialysate excretion. The phar-
macokinetic profile of quinaprilat in these CAPD patients was similar to that previously
observed in patients with RDND. The elimination half-life of quinaprilat was markedly
prolonged when compared to that in healthy subjects and averaged 20 hours, with only a
small amount of quinaprilat excreted in dial ysate (mean = 2.6% of total dose). In sum-
mary, renal failure prolongs both the half-life as well as the antihypertensive effect of
quinaprilat, and CAPD has little or no effect on the disposition of quinaprilat.
T he treatment of hypertension is an important
adjunct to ongoing care in patients with
chronic, irreversible renal failure who must undergo
maintenance dialysis therapy. Among the treatment
modalities, continuous ambulatory peritoneal dialy-
sis (CAPD) has become more widely employed and
accepted as an alternative to hemodialysis,15 and
CAPD may actually be associated with improvement
in hypertension control and reduced need for anti-
hypertensive agents.1’4’9
Among the antihypertensive agents available, an-
giotensin converting enzyme (ACE) inhibitors are
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sometimes used in patients maintained on dialysis
both to control blood pressure10’11 as well as to re-
duce thirst and limit voluntary fluid intake.12’13 The
action of such agents is subject to alteration in the
presence of renal failure, particularly when the na-
tive drug or its active metabolite is excreted primar-
ily by the kidneys.14’15 Such is the case for the new
AGE inhibitor, quinapril (CI-906; Accupril#{174}; Parke-
Davis, Morris Plains, NJ), as its metabolite, quinapri-
lat (GI-928), is primarily responsible for the thera-
peutic effect and is eliminated primarily by renal
excretion.16’17’21
The pharmacokinetics of quinapril and quinapri-
lat have been described in healthy subjects with
normal renal function,2#{176} in patients with moderate
to severe renal dysfunction (creatinine clearance
9.4-25 mL/min) not yet requiring dialysis (RDND),
and in patients maintained on regular hemodialy-
sis.17 However, the pharmacokinetics and peritoneal
elimination of quinapril and its metabolite, quina-
prilat, have not been studied during GAPD. Thus,
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the current study was undertaken in order to define
the pharmacokinetic profile and to gain information
on the safety of this drug in patients with chronic
renal failure maintained on GAPD.
METHODS
Subjects
Six patients (5 men and 1 woman) with chronic renal
failure and creatinine clearance below 5 mL/min
who were undergoing CAPD in the University of
Michigan dialysis program volunteered for this
study. Patient characteristics are listed in Table I.
After giving informed consent according to the pro-
tocol approved by the Institutional Review Board,
patients were admitted to the Clinical Research
Center.
Experimental Procedures. Following an 8-hour over-
night fast, each patient received a single 20-mg oral
dose of quinapril on the morning of study day 1.
Heparinized blood samples were collected serially
thereafter for 72 hours, each sample immediately
centrifuged and frozen at -20#{176}Cfor later gas chro-
matographic analysis to determine the respective
concentrations of quinapril and quinaprilat. Urine
(when available) and peritoneal dialysate were col-
lected over 48 hours postdose and aliquots were fro-
zen for similar analysis. Vital signs were monitored
regularly after administration of quinapril, and rou-
tine meals were continued 4 hours following the
quinapril dose. GAPD was performed according to
the following schedule for two consecutive 24-hour
periods: two 6-hour cycles, a 4-hour cycle and an
overnight 8-hour cycle, with the glucose concentra-
tion of solution (1.5% to 4.25% Dianeal#{174}; Baxter
Healthcare Corp; Deerfield IL) adjusted to individual
patient requirements for blood pressure or fluid
weight control. Any adverse events were recorded
and treated as necessary.
TABLE I
Patient Characteristics
Patient Age Sex Dry Wt (kg) Diagnosis Medications CAPD (mos)
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Drug Assay and Pharmacokinetic Methods. Plasma,
urine, and dialysate quinapril and quinaprilat con-
centrations were determined using a sensitive and
specific gas chromatographic procedure with elec-
tron capture detection.18 In brief, the method in-
volved extracting samples through a Bond-Elut G18
column, methylating the column eluate with diazo-
methane, extracting the methylated products into
hexane, and derivatizing with trifluoroacetic anhy-
dride. Compounds were quantified using the peak-
height ratio method with a quinapril analog serving
as the internal standard. The gas chromatographic
method for determining both quinapril and quina-
prilat levels has been validated in dialysate (1.5%
and 4.25% glucose concentration) and in nonuremic
human plasma over a range of 50-10,000 ng/mL.
Although rigorous validation of the assay methodol-
ogy in uremic plasma was not performed, assay of
actual patient samples revealed no significant inter-
ference peaks for quinapril or quinaprilat in predose
dialysate, plasma or urine of uremic patients.
Maximum quinapril and quinaprilat plasma con-
centrations (Cmax) and the times at which these
occur (tmax) were determined for corresponding
plasma concentration-time profiles. Areas under
plasma concentration-time profiles (AUC) were de-
termined using the trapezoidal rule. Apparent elimi-
nation rate constants (z) were calculated as the ab-
solute value of the slope of a least-squares linear
regression of natural logarithm (ln) plasma concen-
tration-time profile during the terminal phase. Ap-
parent elimination half-life values (t112) were calcu-
lated as 1n2/z. Apparent plasma quinapril and quin-
aprilat clearances (Glp) were calculated by dividing
quinapril dose by the respective quinapril or quina-
prilat AUC.18’19
RESULTS
In general, quinapril was well tolerated by CAPD
patients. Four patients experienced mild transient
symptoms, including itching, cough, headache, and
nausea without vomiting, occurring within several
hours of dosing during the first day. Two patients
experienced symptomatic reduction in blood pres-
sure which responded to oral fluid administration
and/or reduction in dialysate glucose concentra-
tion.
The time courses of the mean arterial blood pres-
sure (MAP = diastolic pressure plus one third of the
difference between systolic and diastolic pressure)
and plasma concentrations of quinapril and quina-
Figure 1. Time course of mean arterial pressure (MAP) and quinapril and quinaprilat plasma concentrations for Patient 1. Open circles
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prilat for patient I are presented in Figure 1. This
sustained reduction in blood pressure, beginning 2
to 4 hours postdose and lasting up to 48 hours, was
observed four of the six subjects. Furthermore, the
reduction in MAP corresponded with the time
course of quinaprilat concentration, particularly
with quinaprilat concentrations persisting above 90
ng/mL for more than 33 hours postdose. Mean
changes in MAP and quinaprilat concentration for
all six patients, are presented in Figure 2, showing
correspondence of MAP reduction with the quina-
prilat plasma concentration.
Pharmacokinetic results are presented in Table II.
Peak quinapril plasma occurred at 0.5 to 3 hours
postdose and ranged from 53 to 225 ng/mL (mean
= 107 ± 67 ng/mL). Quinapril half-life averaged 1.0
± 0.3 hours (range = 0.7 to 1.5 hr), and plasma clear-
ance averaged 2207 ± 1621 mL/min. Peak quinapri-
lat concentration occurred from 3 to 9 hours post-
dose and ranged from 531 to 845 ng/mL (mean = 689
± 124 ng/ml). Quinaprilat half-life averaged 20.1
± 10.1 hours (range = 11.0 to 37.4 hr), and plasma
clearance averaged 18.9 ± 8.4 mL/min. Quinaprilat
dialysate concentrations reached less than 10% of
corresponding average quinaprilat plasma concen-
trations during the 6-hour intervals of peritoneal
equilibration. Overall peritoneal dialysis clearance
of quinaprilat was less than 1 mL/min, and less than
5% of the administered quinapril was recovered as
quinaprilat in peritoneal dialysate during the 48
hours postdose. Negligible amounts of quinaprilat
were recovered in the urine of the two patients with
available urine output.
DISCUSSION
The results of the present study confirm previous
reports that renal failure prolongs the half-life of the
quinaprilat but does not alter significantly the con-
version of quinapril to quinaprilat.16’17’2#{176} The rate
and extent of quinapril absorption, the conversion of
quinapril to quinaprilat as assessed by AUC, Cmox
and tmax values, and the rate of quinapril and quina-
prilat elimination as assessed by apparent t112, were
Figure 2. Time course of average percent change in mean arterial pressure (MAP) from initial baseline and average quinaprilat plasma
concentration for all six patients. Open circles = mean arterial pressure (MAP) and closed circles = quinaprilat concentration.
* C,,. = maximum plasma concentration; t = time to C,,.; AUC area
under plasma concentration-time curve from; fig = apparent elimination half-
life; z = apparent elimination rate constant.
t Mean values for six CAPO patients from present study and for seven RDND
patients from references 16 and 20.
TABLE II
Mean Pharmacokinetic Values for Six Patients
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found not to differ markedly among patients main-
tained on GAPD when compared to patients with
RDND, as shown in Table III.
Furthermore, CAPD appears to have little effect
on quinaprilat disposition. Quinaprilat plasma clear-
ance values observed in patients on GAPD (range
9.1 to 30.3 mL/min) are similar to those previously
reported in patients with RDND (range = 12.3 to 46.5
mL/min),17 and quinaprilat appeared only in small
amounts in peritoneal dialysate (0.7% to 4.1% of ad-
ministered quinapril dose). This limitation in perito-
neal clearance of quinaprilat may be due, in part, to
the high degree of plasma protein binding, approxi-
mately 97%, previously reported for quinaprilat,18
resulting in very low concentrations of free metabo-
lite for transperitoneal diffusion.
The pharmacodynamic results of the present
study are limited to only six patients; however, these
results suggest that the blood pressure reduction in
patients with chronic renal failure maintained on
CAPD following quinapril administration may be
prolonged for more than 24 hours and are associated
with plasma quinaprilat levels exceeding 90 ng/mL.
In view of the potential for significant reduction in
blood pressure in this patient population, it is im-
portant to recognize the need for caution when ini-
tiating AGE inhibitor therapy in patients with mod-
erate or severe renal failure.
In conclusion, a single 20-mg oral dose of quinapril
was generally well tolerated by patients having
chronic renal failure on GAPD, producing reduc-
tions in blood pressure that were long lasting. Quin-
april and quinaprilat pharmacokinetics in patients
on CAPD were similar to those observed in patients
with moderate to severe renal dysfunction not yet
Quinapril Quinaprilat
Max Plasma Concentration
(ng/mL) 107 (67) 689 (124)
lime of Max
Concentration (hr) 1.3 (1.0) 5.4 (2.5)
Half-Life (hr) LO (0.3) 20.1 (10.1)
Plasma Clearance
(mL/min) 2207 (1621) 19 (8.3)*
Dialysate Excretion
(% of dose) minimal 2.6 (1.2)
Urinary Excretion
(% of dose) minimal minimal
All values mean (standard deviation).
TABLE III
Pharmacokinetic Parameters, Comparing CAPD











Cmax(ng/mL) 107 161 689 885
tmax(hr) 1.3 1.3 5.4 3.6
AUC(ng.hr/mL) 205 288 21283 16540
t112 (hr) 1.01 0.9 20.1 12.5
z (1/hr) 0.72 0.79 0.04 0.06
on dialysis. Thus, CAPD had little effect on the dis-
position of quinaprilat.
Invaluable assistance was provided by the nursing staff of the
Clinical Research Center at University of Michigan Medical
Center.
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